Switching within the class of IL-17 inhibitors for the treatment of plaque psoriasis: A real-world retrospective study.
作者信息
Koumprentziotis Ioannis-Alexios, Rompoti Natalia, Stefanaki Irene, Vavouli Charitomeni, Papoutsaki Marina, Politou Maria, Stratigos Alexander, Nicolaidou Electra
机构信息
1st Department of Dermatology-Venereology, Medical School, National and Kapodistrian University of Athens, "A. Sygros" Hospital for Skin and Venereal Diseases, Athens, Greece.
出版信息
Australas J Dermatol. 2025 Mar;66(2):101-104. doi: 10.1111/ajd.14396. Epub 2024 Dec 12.
Abstract
摘要
相似文献
1
Switching within the class of IL-17 inhibitors for the treatment of plaque psoriasis: A real-world retrospective study.在白细胞介素-17抑制剂类别内转换用于治疗斑块状银屑病：一项真实世界回顾性研究。
Australas J Dermatol. 2025 Mar;66(2):101-104. doi: 10.1111/ajd.14396. Epub 2024 Dec 12.
2
Bimekizumab-bkzx for the Treatment of Plaque Psoriasis: A Drug Review.用于治疗斑块状银屑病的比美吉珠单抗-bkzx：药物综述
Ann Pharmacother. 2025 Jun;59(6):577-584. doi: 10.1177/10600280241288553. Epub 2024 Oct 19.
3
Effectiveness and safety of bimekizumab for the treatment of plaque psoriasis: a real-life multicenter study-IL PSO (Italian landscape psoriasis).比美吉珠单抗治疗斑块状银屑病的有效性和安全性：一项真实世界多中心研究-IL PSO（意大利银屑病情况）
Front Med (Lausanne). 2023 Aug 8;10:1243843. doi: 10.3389/fmed.2023.1243843. eCollection 2023.
4
Efficacy and Safety of bimekizumab in elderly patients: real-world multicenter retrospective study - IL PSO (Italian Landscape Psoriasis).比美吉珠单抗治疗老年患者的疗效和安全性：真实世界多中心回顾性研究-IL PSO（意大利银屑病景观）。
J Dermatolog Treat. 2024 Dec;35(1):2393376. doi: 10.1080/09546634.2024.2393376. Epub 2024 Aug 20.
5
Intra-class switch among interleukin-17 inhibitors for the treatment of plaque psoriasis: a single-center experience.用于治疗斑块状银屑病的白细胞介素-17抑制剂类间的换药：单中心经验
Dermatol Reports. 2024 Nov 12. doi: 10.4081/dr.2024.10080.
6
The utility of interleukin-23 intraclass switching in the treatment of plaque psoriasis: a retrospective review of 43 cases.白细胞介素-23 类别转换在斑块状银屑病治疗中的效用：43 例回顾性研究
Clin Exp Dermatol. 2024 Dec 23;50(1):137-140. doi: 10.1093/ced/llae305.
7
Bimekizumab efficacy and safety in patients with moderate-to-severe plaque psoriasis who switched from adalimumab, ustekinumab or secukinumab: results from phase III/IIIb trials.在从阿达木单抗、乌司奴单抗或司库奇尤单抗转换治疗的中重度斑块型银屑病患者中，比美吉珠单抗的疗效和安全性：III 期/IIIb 期试验结果。
Br J Dermatol. 2023 Feb 22;188(3):330-340. doi: 10.1093/bjd/ljac089.
8
9
Bimekizumab for the Treatment of Plaque Psoriasis with Involvement of Genitalia: A 16-Week Multicenter Real-World Experience - IL PSO (Italian Landscape Psoriasis).比美吉珠单抗治疗累及生殖器的斑块状银屑病：一项为期16周的多中心真实世界研究——IL PSO（意大利银屑病概况）
Dermatol Pract Concept. 2024 Apr 1;14(2):e2024052. doi: 10.5826/dpc.1402a52.
10
Real-world experience of bimekizumab for plaque psoriasis in adult patients with prior exposure to interleukin-17 inhibitors: A 16-week multicenter retrospective review.在既往使用过白细胞介素-17抑制剂的成年斑块状银屑病患者中使用比美吉珠单抗的真实世界经验：一项为期16周的多中心回顾性研究。
J Am Acad Dermatol. 2024 Dec;91(6):1265-1267. doi: 10.1016/j.jaad.2024.07.1515. Epub 2024 Aug 23.
本文引用的文献
1
Drug survival, effectiveness and safety of ixekizumab for moderate-to-severe psoriasis up to 5 years.司库奇尤单抗治疗中重度银屑病长达5年的药物留存率、有效性及安全性
J Eur Acad Dermatol Venereol. 2024 Mar;38(3):568-575. doi: 10.1111/jdv.19682. Epub 2023 Dec 26.
2
Bimekizumab efficacy and safety in patients with moderate-to-severe plaque psoriasis who switched from adalimumab, ustekinumab or secukinumab: results from phase III/IIIb trials.在从阿达木单抗、乌司奴单抗或司库奇尤单抗转换治疗的中重度斑块型银屑病患者中，比美吉珠单抗的疗效和安全性：III 期/IIIb 期试验结果。
Br J Dermatol. 2023 Feb 22;188(3):330-340. doi: 10.1093/bjd/ljac089.
3
Brodalumab in plaque psoriasis: Real-world data on effectiveness, safety and clinical predictive factors of initial response and drug survival over a period of 104 weeks.布罗达单抗治疗斑块状银屑病：104周期间关于有效性、安全性以及初始反应和药物留存的临床预测因素的真实世界数据。
J Eur Acad Dermatol Venereol. 2023 Apr;37(4):689-697. doi: 10.1111/jdv.18825. Epub 2023 Jan 4.
4
Efficacy of switches within the class of IL-17 inhibitors: An analysis of data from the Czech nationwide registry of psoriatic patients receiving biological/targeted therapy (BIOREP).IL-17 抑制剂类药物的转换疗效：捷克接受生物/靶向治疗（BIOREP）的银屑病患者全国登记处数据分析
Dermatol Ther. 2022 Oct;35(10):e15772. doi: 10.1111/dth.15772. Epub 2022 Sep 5.
5
Real-life intraclass switch among IL-17 inhibitors in psoriasis: results from a single-centre, 24-week, retrospective study.银屑病中白细胞介素-17抑制剂在实际临床中的转换：一项单中心、24周回顾性研究的结果
J Eur Acad Dermatol Venereol. 2022 Nov;36(11):e952-e953. doi: 10.1111/jdv.18381. Epub 2022 Jul 7.
6
Efficacy of a second interleukin 17 inhibitor in patients with psoriasis: A systematic review and meta-analysis.银屑病患者中第二种白细胞介素 17 抑制剂的疗效：系统评价和荟萃分析。
J Am Acad Dermatol. 2021 Jan;84(1):130-138. doi: 10.1016/j.jaad.2020.07.085. Epub 2020 Jul 28.
7
Real-world data from a single Greek centre on the use of secukinumab in plaque psoriasis: effectiveness, safety, drug survival, and identification of patients that sustain optimal response.来自希腊单一中心的关于司库奇尤单抗治疗斑块状银屑病的真实世界数据：有效性、安全性、药物留存率以及持续获得最佳反应的患者识别。
J Eur Acad Dermatol Venereol. 2020 Jun;34(6):1240-1247. doi: 10.1111/jdv.16202. Epub 2020 Feb 28.
8
Successful intra-class switching among IL-17 antagonists: a multicentre, multinational, retrospective study.IL-17 拮抗剂的成功同类内转换：一项多中心、多国回顾性研究。
Arch Dermatol Res. 2019 Jul;311(5):421-424. doi: 10.1007/s00403-019-01907-y. Epub 2019 Mar 16.
9
Biologic switching between interleukin 17A antagonists secukinumab and ixekizumab: a 12-week, multicenter, retrospective study.白细胞介素17A拮抗剂司库奇尤单抗和依奇珠单抗之间的生物转换：一项为期12周的多中心回顾性研究。
J Eur Acad Dermatol Venereol. 2019 Jan;33(1):e7-e8. doi: 10.1111/jdv.15100. Epub 2018 Jun 20.
10
A Review of Switching Biologic Agents in the Treatment of Moderate-to-Severe Plaque Psoriasis.《中重度斑块状银屑病生物制剂转换治疗的研究进展》
Clin Drug Investig. 2018 Mar;38(3):191-199. doi: 10.1007/s40261-017-0603-3.
Zotero 插件